Clinical Trials at City of Hope Comprehensive Cancer Center

As of June 2026, 98 paid clinical trials are recruiting at City of Hope Comprehensive Cancer Center, located at 1500 DUARTE RD, DUARTE, CA 91010-3012, phone (800) 826-4673 in Duarte, California. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: June 12, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

98 clinical trials at City of Hope Comprehensive Cancer Center

·Clear filters·↓ Download CSV

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

for Relapsed and/or Refractory Multiple Myeloma

13 locations incl. Birmingham

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Sex: All·Age: 18+

Code: NCT06153251·Phase 1·Recruiting

Apply to this trial

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

for Relapsed/Refractory Non-Hodgkin Lymphoma

14 locations incl. Phoenix

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT06090539·Phase 1, Phase 2·Recruiting

Apply to this trial

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

for Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation

13 locations incl. Duarte

Sponsor: National Cancer Institute (NCI)

Sex: Male·Age: 18+

Code: NCT05691465·Phase 2·Recruiting

Apply to this trial

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

for Anatomic Stage II Breast Cancer AJCC v8

Drug: Durvalumab

536 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06058377·Phase 3·Recruiting

Apply to this trial

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

for Mantle Cell Lymphoma

237 locations incl. Little Rock

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 60+

Code: NCT05976763·Phase 3·Recruiting

Apply to this trial

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

for Breast Cancer

1208 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: Female·Age: 18 - 60

Code: NCT05879926·Phase 3·Recruiting

Apply to this trial

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

for Grade 3b Follicular Lymphoma

104 locations incl. Tucson

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT05890352·Phase 2·Recruiting

Apply to this trial

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

for Anatomic Stage I Breast Cancer AJCC v8

955 locations incl. Birmingham

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT05929768·Phase 3·Recruiting

Apply to this trial

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

for Metastatic Breast Cancer

20 locations incl. Gilbert

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT05894239·Phase 3·Recruiting

Apply to this trial

A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma

for Cardiovascular Disorder

31 locations incl. Mobile

Sponsor: Children's Oncology Group

Sex: All·Age: 7+

Code: NCT05705531·Recruiting

Apply to this trial

Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes

for Metastatic Malignant Solid Neoplasm

22 locations incl. Duarte

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05687110·Phase 1·Recruiting

Apply to this trial

Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy

for Lymphoid Leukemia

22 locations incl. Tucson

Sponsor: Stanford University

Sex: All·Age: Up to 26

Code: NCT05865301·Recruiting

Apply to this trial

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

for Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

Drug: Nivolumab

390 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 5 - 60

Code: NCT05675410·Phase 3·Recruiting

Apply to this trial

Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors

for Anatomic Stage I Breast Cancer AJCC v8

7 locations incl. Alhambra

Sponsor: Jonsson Comprehensive Cancer Center

Sex: Female·Age: All ages

Code: NCT05595499·Phase 2·Recruiting

Apply to this trial

Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

for Recurrent Glioblastoma, IDH-Wildtype

Drug: Selinexor

36 locations incl. Phoenix

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05432804·Phase 1, Phase 2·Recruiting

Apply to this trial

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

for Metastatic Salivary Gland Carcinoma

150 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT05408845·Phase 2·Recruiting

Apply to this trial

A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

for High Grade Osteosarcoma

Drug: Cabozantinib

175 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: Up to 40

Code: NCT05691478·Phase 2, Phase 3·Recruiting

Apply to this trial

SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer

for Oropharyngeal Cancer

26 locations incl. Corona

Sponsor: Canadian Cancer Trials Group

Sex: All·Age: 18+

Code: NCT05451004·Phase 3·Recruiting

Apply to this trial

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

for Metastatic Renal Cell Carcinoma

313 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT05327686·Phase 2·Recruiting

Apply to this trial

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

for Lung Adenocarcinoma

34 locations incl. Buena Park

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05198830·Phase 2·Recruiting

Apply to this trial

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

for Endometrial Carcinoma

403 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: Female·Age: 18+

Code: NCT05256225·Phase 3·Recruiting

Apply to this trial

Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

for Advanced Malignant Solid Neoplasm

36 locations incl. Duarte

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05327010·Phase 2·Recruiting

Apply to this trial

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

for Recurrent B-Cell Non-Hodgkin Lymphoma

Drug: Nivolumab

9 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05272384·Phase 1·Recruiting

Apply to this trial

LYL273 for Patients With Relapsed or Refractory mCRC

for Colorectal Cancer

4 locations incl. Duarte

Sponsor: Lyell Immunopharma, Inc.

Sex: All·Age: 18+

Code: NCT05319314·Phase 1, Phase 2·Recruiting

Apply to this trial

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

for Stage III Colon Cancer

1021 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT05174169·Phase 2, Phase 3·Recruiting

Apply to this trial

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

for Renal Pelvis and Ureter Urothelial Carcinoma

Drug: Durvalumab

258 locations incl. Kingman

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04628767·Phase 2, Phase 3·Recruiting

Apply to this trial

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

for Advanced Systemic Mastocytosis (AdvSM)

14 locations incl. Birmingham

Sponsor: Cogent Biosciences, Inc.

Sex: All·Age: 18+

Code: NCT04996875·Phase 2·Recruiting

Apply to this trial

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

for Metastatic Colorectal Cancer

35 locations incl. Birmingham

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT04929223·Phase 1·Recruiting

Apply to this trial

A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

for Endometrial Cancer

21 locations incl. Duarte

Sponsor: Alliance Foundation Trials, LLC.

Sex: Female·Age: 18+

Code: NCT04486352·Phase 1, Phase 2·Recruiting

Apply to this trial

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial

for Metastatic Clear Cell Renal Cell Carcinoma

387 locations incl. Birmingham

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT04510597·Phase 3·Recruiting

Apply to this trial

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

for Chronic Lymphocytic Leukemia

621 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04269902·Phase 3·Recruiting

Apply to this trial

Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)

for Recurrent T Acute Lymphoblastic Leukemia

163 locations incl. Birmingham

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 12+

Code: NCT04315324·Phase 1, Phase 2·Recruiting

Apply to this trial

Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

for Retroperitoneal Sarcoma

109 locations incl. Birmingham

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Sex: All·Age: 18+

Code: NCT04031677·Phase 3·Recruiting

Apply to this trial

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

for Locally Advanced Pancreatic Adenocarcinoma

Drug: Peposertib

44 locations incl. Duarte

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04172532·Phase 1, Phase 2·Recruiting

Apply to this trial

Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

for Recurrent Mantle Cell Lymphoma

1 location in Duarte

Sponsor: City of Hope Medical Center

Sex: All·Age: 18 - 75

Code: NCT04484012·Phase 2·Recruiting

Apply to this trial

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

for Down Syndrome

Drug: Nivolumab

202 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 1 - 30

Code: NCT04546399·Phase 2·Recruiting

Apply to this trial

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

for Ovarian Cancer

Drug: Cemiplimab

13 locations incl. Duarte

Sponsor: Regeneron Pharmaceuticals

Sex: Female·Age: 18+

Code: NCT04590326·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

for Non-small Cell Lung Cancer

38 locations incl. Duarte

Sponsor: Genentech, Inc.

Sex: All·Age: 18+

Code: NCT04302025·Phase 2·Recruiting

Apply to this trial

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

for Metastatic Castration-Resistant Prostate Carcinoma

32 locations incl. Duarte

Sponsor: National Cancer Institute (NCI)

Sex: Male·Age: 18+

Code: NCT04071236·Phase 1, Phase 2·Recruiting

Apply to this trial

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

for Biochemically Recurrent Prostate Carcinoma

Drug: Apalutamide

342 locations incl. Anchorage

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: Male·Age: 18+

Code: NCT04423211·Phase 3·Recruiting

Apply to this trial